Risk factors
BioRestorative Therapies (BRTX) risk factors
Item 1A of every BioRestorative Therapies, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks5 new1 dropped6 reworded
Company faces Nasdaq delisting threat after shares dropped to $0.33, and key executive employment agreements expired in March 2026 without extension.
Filed Mar 26, 2026 - FY2024 10-K risk factors51 risks
The company relies heavily on ongoing financing to fund its pre-revenue cell therapy development, particularly for product candidate BRTX-100.
Filed Mar 28, 2025